Course 3: Pharmacovigilance Inspections Part 1: Readiness, Conducting, Findings, and Report-Outs
Richard Abate, MS, RPh
- Lead Consumer Safety Officer
- FDA, United States
Richard Abate serves as the Postmarketing Adverse Drug Experience (PADE) Compliance Team Leader in CDER's Office of Compliance. Rick joined FDA in 2006 as a Safety Evaluator in CDER's Office of Surveillance and Epidemiology and moved to Office of Compliance in 2013. Rick obtained a BS in Pharmacy from the University of Maryland and a MS in Pharmacy Practice from the University of North Carolina.
Marcia Gelber, PharmD, RPh
- Food and Drug Administration, United States
Marcia Gelber joined FDA in 2009 as a Consumer Safety Officer in CDER’s Office of Compliance, Office of Scientific Investigations where she is responsible for planning and evaluating drug safety inspections and serves as a consultant to FDA field personnel on problems encountered during inspections. Prior to joining FDA, Marcia worked in the pharmaceutical industry for over 25 years. She is a registered pharmacist and graduate of the University of the Sciences in Philadelphia, PA. Marcia enjoys teaching drug safety and pharmacovigilance because safe medications improve lives.
Shiferaw Kibriye, PharmD
- Medical Quality Assurance. Head of Inspection Management and GLP QA
- Pfizer Inc., United States
Shiferaw is currently the Head of Inspection Management, within Medical Quality Assurance at Pfizer. Previous to his current role, he was an Executive Director, Therapeutic Area Head within Safety Evaluation and Reporting within the Worldwide Safety organization at Pfizer. Previous to these roles, Shiferaw worked in the Global Investigator Initiated Research (IIR) group as a Director/Team Leader in charge of all IIRs in the Specialty Care and Emerging Markets Business Units.
- Principal Consultant
- NDA Regulatory Science Ltd, United Kingdom
Helen Powell has over 30 years’ experience in the pharmaceutical industry in large pharma, CRO and consultancy sectors. She brings significant expertise in auditing (GCP, PV and auditing of corporate legal risks), has managed global audit teams across the USA, Asia Pacific and Europe, as well as facilitating PV and GCP inspections in these territories.
Michael Richardson, MD, FFPM
- International GPV&E and EU QPPV
- Bristol-Myers Squibb, United Kingdom
Currently International Head of BMS’s Pharmacovigilance Function and EU QPPV based in the UK. He is medically qualified graduating from Stellenbosch University and specialised in Obstetrics and Gynaecology. He practiced in Cambridge prior to joining the Pharmaceutical industry in Clinical Research and then Medical affairs. He has worked in major MNCs across the globe and heading up Research and Development in Asia. He is also a long serving member of the EFPIA PV committee, served on ICH E2C(R2) EWG and Q&A IWG. Additionally Heads BMS Global Risk Management function.